Company Name: |
A.T.CHEMICAL
|
Tel: |
0755-86655561 81899190 |
Email: |
Jeffreyxu@atchem.net |
Products Intro: |
|
|
| Efalizumab Basic information |
Product Name: | Efalizumab | Synonyms: | Efalizumab;Hu 1124;Raptiva;Unii-xx2mn88N5d;Xanelim | CAS: | 339155-58-7 | MF: | | MW: | 0 | EINECS: | | Product Categories: | | Mol File: | Mol File | |
| Efalizumab Chemical Properties |
| Efalizumab Usage And Synthesis |
Uses | Treatment of transplant rejections; antipsoriatic (immunomodulator monoclonal antibody which decreases the activation, migration, and adhesion of T-cells). hu1124; anti-CD11a.
Efalizumab (Raptiva) is a humanized monoclonal antibody that binds to the CD11a subunit of LFA-1. It blocks the interaction of LFA-1 with ICAM-1, thereby interfering with T-cell activation and trafficking. Efalizumab is FDA approved at 1.0 mg/kg/week by subcutaneous injection. Common side effects include mild headache, fever, chills, nausea, or myalgia within the first 48 hours of injection in the first 2 to 3 weeks of therapy. Immune-mediated thrombocytopenia is rare. Worsening of psoriasis may occur after discontinuation of therapy or in unresponsive patients during therapy. Transitioning patients to alternative therapies may minimize this risk. | Pharmacology | Efalizumab (Raptiva) is a humanized monoclonal antibody that binds to the
CD11a subunit of LFA-1. It blocks the interaction of LFA-1 with ICAM-1,
thereby interfering with T-cell activation and trafficking. Efalizumab is FDA approved at 1.0 mg/kg/week by subcutaneous injection. | Side effects | Common side effects
include mild headache, fever, chills, nausea, or myalgia within the first 48
hours of injection in the first 2 to 3 weeks of therapy. Immune-mediated
thrombocytopenia is rare. Worsening of psoriasis may occur after discontinuation
of therapy or in unresponsive patients during therapy. Transitioning
patients to alternative therapies may minimize this risk. |
| Efalizumab Preparation Products And Raw materials |
|